EarningsQ2 2026 Earnings Report
DE:IL3 Q2 2026 EPS Results
Actual EPS€0.50
Consensus EPS€0.43
Beat/MissBeat by +€0.07
One Year Ago EPS€0.40
DE:IL3 Q2 2026 Revenue Results
Actual Revenue€374.92M
Expected Revenue€373.83M
Beat/MissBeat by +€1.09M
YoY Revenue Growth+0.76%
Earnings Announcement Details
QuarterQ2 2026
Date07/29/2026
TimeBefore Open
Conference CallWednesday, July 29, 2026
DE:IL3 Upcoming Earnings
Integra Lifesciences's next earnings date is estimated for October 21, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:IL3 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized steady, constructive progress: revenue and EPS tracked to guidance with meaningful margin expansion, improved operating cash flow, successful product relaunch momentum (PriMatrix) and a key operational milestone with Braintree restarting to enable the SurgiMend relaunch. Management reaffirmed full-year organic growth and adjusted EPS guidance while outlining cost savings and deleveraging priorities. Offsetting positives are softness in tissue reconstruction and ENT, competitive pressure on MicroMatrix, continued high net debt and the timing risk tied to FDA inspections and refinancing-related interest expense. Overall the positives (execution, margin/cash improvement, product relaunches and supply recovery) substantially outweigh the headwinds, though timing and leverage risks remain.)Company Guidance
Revenue and EPS Delivery
Q2 revenue of $419.0M, up $27M sequentially; reported revenue growth +0.8% YoY and organic growth +0.7% YoY. Adjusted EPS $0.56, up 24% YoY and above the high end of guidance (beat consensus by ~$0.08). Tariff favorability contributed ~$0.05 per share in the quarter.
Margin Expansion
Gross margin improved to 61.3%, up ~60 bps versus prior year (60.7%). Adjusted EBITDA margin was 18.7%, up ~160 bps versus 17.1% in Q2 2025. Management expects FY midpoint expansion vs 2025 of ~60 bps (gross) and ~100 bps (adjusted EBITDA).
Cash Flow Improvement and Deleveraging Progress
Operating cash flow of $22.8M in Q2 vs $8.9M prior year; H1 operating cash flow $35M. Company expects ~ $150M improvement in operating cash flow for the year. Free cash flow was $10.5M with conversion 24%. Net debt $1.6B and consolidated leverage improved to 4.1x from 4.5x at year-end; liquidity ~ $496M (including ~$274M cash).
Operational Milestone — Braintree Restart and Supply Recovery
Successfully restarted manufacturing at the Braintree facility and is building inventory to support a phased SurgiMend relaunch in Q4. Management reports improving supply reliability and stronger fulfillment across the business.
Successful Product Relaunch — PriMatrix Traction
PriMatrix relaunch showing encouraging adoption: revenues recovered to slightly more than 50% of pre-recall levels ~9 months into relaunch and continuing to increase sequentially, supporting confidence in relaunch playbook.
Specialty Surgery Strength
Specialty surgery revenue $309.3M, reported growth +1.7% and organic +1.6%. Global Neurosurgery delivered organic growth of +1.9% driven by Certas Plus, CUSA (double-digit growth) and BactiSeal; instruments expected to grow low single digits for the year.
Transformation and Cost Savings
Transformation initiatives driving $25M–$30M of expected cost savings in 2026 and an incremental $10M–$15M annualized in 2027; these actions contributed to improved SG&A control and higher adjusted EPS.
Regulatory Progress Toward PMA Labels
SurgiMend has an approvable decision pending a successful pre-approval inspection at Braintree; company expects SurgiMend approval earlier in 2027 and DuraSorb later in 2027, positioning expanded indications in implant-based breast reconstruction.
DE:IL3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed